Literature DB >> 17642854

Study of genital lesions.

B H Anand Kumar1, D Vijaya, R Ravi, R R Reddy.   

Abstract

A total of one hundred patients (75 males and 25 females) age ranged from 17-65 years with genital lesions attending the STD clinic of Bowring and LC Hospitals Bangalore constituted the study group. Based on clinical features, the study groups were classified as syphilis (39), chancroid (30), herpes genitalis (13), condylomato lato (9), LGV (7t condylomata acuminata (5), genital scabies (3), granuloma inguinole (2) and genital candidiasis (1). In 68% microbiological findings confirmed the clinical diagnosis. Of the 100 cases 13% and 2% were positive for HIV antibodies and HbsAg respectively.

Entities:  

Year:  2003        PMID: 17642854

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  4 in total

1.  Passive immunization with a polyclonal antiserum to the hemoglobin receptor of Haemophilus ducreyi confers protection against a homologous challenge in the experimental swine model of chancroid.

Authors:  Isabelle Leduc; William G Fusco; Neelima Choudhary; Patty A Routh; Deborah M Cholon; Marcia M Hobbs; Glen W Almond; Paul E Orndorff; Christopher Elkins
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

2.  Current status of acquired syphilis: A hospital-based 5-year study.

Authors:  Arpita Jain; Vibhu Mendiratta; Ram Chander
Journal:  Indian J Sex Transm Dis AIDS       Date:  2012-01

3.  A clinico-epidemiological study of ulcerative sexually transmitted diseases with human immunodeficiency virus status.

Authors:  Bhavesh Mehta
Journal:  Indian J Sex Transm Dis AIDS       Date:  2014-01

4.  Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes.

Authors:  Martijn J Stax; Emily E I M Mouser; Thijs van Montfort; Rogier W Sanders; Henry J C de Vries; Henk L Dekker; Carolina Herrera; Dave Speijer; Georgios Pollakis; William A Paxton
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.